News | August 25, 2008

Corgenix, BG Medicine to Collaborate in Cardiac Risk Assessment Studies

August 26, 2008 - Corgenix Medical Corp. announced its collaboration with BG Medicine whereby Corgenix' AtherOx products will be included in studies conducted by BG Medicine to predict near-term risk of first myocardial infarction (MI).

Under the terms of the collaboration agreement, Corgenix will provide several of its products for the studies conducted by BG Medicine, including the FDA-cleared IgG Anti-AtherOx Kit, as well as the investigational Anti-AtherOx IgM and AtherOx kits. Corgenix may use the data generated by BG Medicine with the AtherOx technology products for regulatory and commercialization purposes in exchange for certain considerations.

The AtherOx technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/B2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus and lupus-like disorders. Corgenix licensed this technology in 2002, and is developing additional products utilizing this unique platform.

For more information: www.corgenix.com


Related Content

News | Cardiac Diagnostics

Aug. 13, 2024 – The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for ...

Home August 15, 2024
Home
Feature | Cardiac Diagnostics | By Robert L. Quigley, MD, DPhil

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes ...

Home January 23, 2024
Home
News | Cardiac Diagnostics

September 5, 2023 — GE HealthCare announced the launch of a handheld, wireless ultrasound imaging system designed for ...

Home September 05, 2023
Home
Feature | Cardiac Diagnostics | By Kelly Patrick

The global ambulatory diagnostic cardiology market was valued at $2.6 billion in 2022 and is forecast to rise to $3.3 ...

Home May 15, 2023
Home
News | Cardiac Diagnostics

February 8, 2023 — Results of research that identified new causes of Atherosclerotic Coronary Artery Disease, or ASCAD ...

Home February 08, 2023
Home
News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Home
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Home
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Subscribe Now